AbCellera Biologics (ABCL) vs Dyne Therapeutics (DYN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 176.1% versus a loss of 26.8%. Over five years, DYN leads with a +5.4% price change compared with -30.7% for ABCL. AbCellera Biologics is the larger company by market cap ($3.16 billion vs $2.90 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | DYN |
|---|---|---|
| Share price | $9.69 | $15.50 |
| Market cap | $3.16B | $2.90B |
| 1-day change | -7.45% | -3.31% |
| YTD return | +183.33% | -20.76% |
| 1-year return | +176.07% | -26.82% |
| 5-year return | -30.74% | +5.37% |
| EPS (TTM) | $-0.48 | $-3.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | — |
| Revenue growth (YoY) | +160.56% | — |
| Net income (latest FY) | $-146.41M | $-446.21M |
| Operating margin | -288.98% | — |
| Net margin | -194.88% | — |
| 52-week high | $15.02 | $27.31 |
| 52-week low | $2.75 | $14.00 |
| Distance from 52-week high | -35.46% | -43.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +92.67% | +121.48% |
| Average volume | 4.34M | 2.94M |
| Shares outstanding | 326.62M | 187.39M |
| Employees | 562 | 322 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed DYN by 202.9 percentage points over the past year.
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees
ABCL vs DYN FAQ
Which is bigger, AbCellera Biologics or Dyne Therapeutics?
AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.16B compared with $2.90B for Dyne Therapeutics (DYN).
Which stock has performed better over the past year, ABCL or DYN?
ABCL returned +176.07% over the past 12 months, compared with -26.82% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Dyne Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.